Industry News

FDA Market Clearance for Therapeutic Plasma Exchange Announced

Published in Blood Weekly, June 24th, 1996

Haemonetics Corp., Braintree, Massachusetts, announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to market its MCS and MCS+ apheresis systems for use in Therapeutic Plasma Exchange.

Therapeutic Plasma Exchange is the replacement of a patient's plasma with either fresh frozen plasma or albumin. This medical procedure is prescribed for an increasing number of indications, including autoimmune diseases such as Thrombotic Thrombocytopenic Purpura (TTP), Myasthenia Gravis and Guillian-Barre. The typical patient receives multiple treatments over weeks or months and, in some cases, years.

A trained technician or nurse...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (1996-06-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry